(Q38263148)

1 September 2017

1 reference

title

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer (English)

1 reference

1 September 2017

0 references

1 reference

Jeff A Engle

1

1 reference

1 September 2017

Jill M Kolesar

series ordinal

2

1 reference

1 September 2017

publication date

1 November 2014

1 reference

American Journal of Health-System Pharmacy

1 September 2017

published in

1 reference

1 September 2017

volume

71

1 reference

1 September 2017

issue

22

1 reference

1 September 2017

page(s)

1933-1938

1 reference

1 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

ERBB receptors and cancer: the complexity of targeted inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130654

31 March 2020

Identifiers

DOI

10.2146/AJHP130654

1 reference

1 September 2017

1 reference